Ignyta (RXDX) vs. Cascadian Therapeutics (CASC) Head to Head Review

Ignyta (NASDAQ: RXDX) and Cascadian Therapeutics (NASDAQ:CASC) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.

Volatility & Risk

How to Become a New Pot Stock Millionaire

Ignyta has a beta of 184.87, suggesting that its share price is 18,387% more volatile than the S&P 500. Comparatively, Cascadian Therapeutics has a beta of 3.79, suggesting that its share price is 279% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Ignyta and Cascadian Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ignyta 0 4 1 0 2.20
Cascadian Therapeutics 1 2 2 0 2.20

Ignyta presently has a consensus price target of $26.40, suggesting a potential downside of 2.04%. Cascadian Therapeutics has a consensus price target of $7.00, suggesting a potential downside of 30.14%. Given Ignyta’s higher probable upside, research analysts clearly believe Ignyta is more favorable than Cascadian Therapeutics.

Profitability

This table compares Ignyta and Cascadian Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ignyta N/A -113.09% -68.72%
Cascadian Therapeutics N/A -43.53% -40.90%

Insider and Institutional Ownership

72.3% of Ignyta shares are held by institutional investors. Comparatively, 81.4% of Cascadian Therapeutics shares are held by institutional investors. 13.1% of Ignyta shares are held by company insiders. Comparatively, 1.1% of Cascadian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Ignyta and Cascadian Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ignyta N/A N/A -$103.63 million N/A N/A
Cascadian Therapeutics N/A N/A -$56.93 million N/A N/A

Summary

Cascadian Therapeutics beats Ignyta on 5 of the 8 factors compared between the two stocks.

Ignyta Company Profile

Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

Cascadian Therapeutics Company Profile

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive News & Ratings for Ignyta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply